Docoh
Loading...

Thu. 7 Oct 2021, 5:03am ETBenzinga
In: News, Price Target, Initiation, Analyst Ratings
Jefferies analyst Akash Tewari initiates coverage on Global Blood Therapeutics (NASDAQ:GBT) with a Buy rating and announces Price Target of $68.